



## **Evogene Financial Results for the Fourth Quarter and Full Year of 2019 Earnings Announcement Schedule**

**Rehovot, Israel – February 12, 2020** - Evogene Ltd. (NASDAQ, TASE: EVGN), a leading company in leveraging computational biology to design novel products for life-science-based industries including: human health, agriculture and industrial applications announces today that it will release its financial results for the fourth quarter and full year of 2019 on Wednesday, March 4, 2020.

On the day of the announcement, the Company's management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at [www.evogene.com](http://www.evogene.com).

A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-326-9310 toll free from the United States, or +972-3-925-5904 internationally. The replay will be accessible through March 4, 2019, and an archive of the webcast will be available on the Company's website.

**-XXX-**



## **About Evogene:**

Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel products for major life science markets through the use of a unique computational predictive biology (CPB) platform incorporating deep scientific understandings and advanced computational technologies.

Today, this platform is utilized by the Company to discover and develop innovative products in the following areas (via subsidiaries or divisions): ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, human microbiome based therapeutics and medical cannabis. Each subsidiary or division establishes its product pipeline and go-to-market, as demonstrated in their collaborations with world-leading companies such as BASF, Bayer, Corteva and ICL. For more information, please visit [www.evogene.com](http://www.evogene.com)

## **Forward Looking Statements**

*This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates" or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene's reports filed with the appropriate securities authority. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.*



Investor Relations Contact:

Rivka Neufeld

Investor Relations and Public Relations Manager

E: [IR@evogene.com](mailto:IR@evogene.com)

T: +972-8-931-1940

Evogene US Investor Relations:

Joseph Green

Edison Group

E: [jgreen@edisongroup.com](mailto:jgreen@edisongroup.com)

T: +1 646-653-7030

Laine Yonker

Edison Group

E: [lyonker@edisongroup.com](mailto:lyonker@edisongroup.com)

T: +1 646-653-7035